Biotechnology 24 July 2026

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point

Iovance Biotherapeutics climbed 43.1% on Thursday following a record quarter for sales. The stock ended the session at $6.21, having peaked at $6.39, which marked a 52-week high. Ahead of Friday’s open, the shares last changed hands at $6.24.

7 August 2026

Biotechnology·NASDAQ:IOVA·Pharmaceuticals·Stock Market

BillionToOne (NASDAQ:BLLN) shares drop 39% after maintained guidance signals weaker second half

BillionToOne stock slid 38.8% to $91.72 as of 3:03 p.m. The company maintained its 2026 sales forecast following a robust quarter. Based on basic shares as of August 3, the decline wiped out approximately $2.75 billion in market capitalization.

6 August 2026

Biotechnology·Earnings·NASDAQ:BLLN·Stock Market

Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions

NEW YORK, August 5, 2026, 06:08 EDT - Shares of Bluejay Diagnostics rose 47% in premarket trading, while warrant funding for the company continues to depend on certain conditions.

5 August 2026

Biotechnology·NASDAQ:BJDX·Stock Market

Autonomix Medical (NASDAQ:AMIX) Shares Surge 400% Following Patent Update Linked to a 2025 Grant

Shares of Autonomix Medical Inc. surged nearly fivefold on Tuesday following the announcement of a cancer-neuromodulation patent. However, federal records indicate the relevant U.S. grant is dated October 2025.

4 August 2026

Biotechnology·NASDAQ:AMIX·Stock Market

Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold

Ensysce shares surged 48% in premarket trading, but the stock must climb an additional 141% to hit Nasdaq’s $1 minimum. Over 80 million shares changed hands ahead of the 9:30 a.m. market open.

4 August 2026

Biotechnology·Nasdaq·NASDAQ:ENSC·Stock Market

Vertex Pharmaceuticals lifts forecast as non-CF portfolio heads into 53% second-half hurdle

Vertex Pharmaceuticals Incorporated lifted its yearly sales forecast as cystic-fibrosis treatments fueled a 12% rise in quarterly revenue. Shares traded almost flat around $470 following hours, after a 1.3% drop to $470.72 at the close.

4 August 2026

Biotechnology·Earnings·NASDAQ:VRTX·Pharmaceuticals·Stock Market

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

A positive FDA decision triggered the movement of nearly $763 million between two melanoma stocks on Friday. Replimune Group saw an increase of around $486 million, while Iovance Biotherapeutics lost approximately $277 million. These figures are based on the most recent common-share counts reported by the companies.

3 August 2026

Biotechnology·NASDAQ:IOVA·NASDAQ:REPL·Pharmaceuticals·Stock Market

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Replimune stock finished Friday at $11.20, gaining 107.0%. The surge came after an FDA advisory panel voted 10–3 in favor of RP1. The company's reported market capitalization jumped by about $485 million to $940.2 million. Trading volume was 33.38 million shares, 7.5 times the usual level.

31 July 2026

Biotechnology·NASDAQ:REPL·Pharmaceuticals·Stock Market

Replimune (NASDAQ:REPL) Shares Surge, Gaining Nearly $600 Million in Equity Value Following FDA Decision

Replimune stock surged approximately 131% to near $12.50 ahead of Friday’s regular trading. A panel of FDA advisers voted 10-3 in favor of RP1’s IGNYTE efficacy data being interpretable and clinically important.

31 July 2026

Biotechnology·NASDAQ:REPL·Stock Market

GlucoTrack, Inc. (NASDAQ:GCTK) surges 95% after LT-100 news, market eyes dilution impact

Shares of GlucoTrack jumped as Lōkahi Therapeutics proposed an easier pathway for LT-100. The fully owned subsidiary is seeking approval for a single subcutaneous injection rather than as many as 15 intradermal injections.

30 July 2026

Biotechnology·NASDAQ:GCTK·Stock Market

Autonomix Medical, Inc. (NASDAQ:AMIX) rises as cash-per-share differential aligns with warrant overhang

Autonomix Medical shares jumped ahead of Wednesday's market open following a balance-sheet update that revealed a significant valuation disparity. Nasdaq trading was shut during regular hours. By 5:55 a.m., premarket volume totaled 3.31 million shares.

29 July 2026

Biotechnology·NASDAQ:AMIX·Stock Market

Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle

Gossamer Bio, Inc. surged 46.6% on Monday, boosted by FDA feedback backing a planned seralutinib submission in September. Shares finished at $0.1994. The rally continued premarket.

28 July 2026

Biotechnology·NASDAQ:GOSS·Pharmaceuticals·Stock Market

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

NEW YORK, July 27, 2026, 3:02 p.m. EDT. Gossamer Bio shares rose sharply after the company outlined its FDA filing strategy, but lingering questions over cash reserves and potential shareholder dilution persist.

27 July 2026

Biotechnology·NASDAQ:GOSS·Pharmaceuticals·Stock Market

SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap

Shares of SELLAS Life Sciences Group, Inc. slid 3.9% on Monday following an 8.3% decline on Friday. The stock reached a low of $9.60 before rebounding to $10.88.

27 July 2026

Biotechnology·NASDAQ:SLS·Pharmaceuticals·Stock Market

Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data

Shares of Capricor Therapeutics, Inc. fell by nearly two-thirds on Monday after U.S. regulators raised concerns over the efficacy data for deramiocel, the company’s treatment aimed at Duchenne muscular dystrophy.

27 July 2026

Biotechnology·Pharmaceuticals·Stock Market

CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test

CSL Limited enters Monday after five straight losses erased 7.4% from its share price, Friday-to-Friday. Shares closed Friday at A$114.22, down 1.3% on the day. The ASX cash market was closed at publication; pre-open begins at 07:00 AEST.

26 July 2026

ASX:CSL·Biotechnology·Pharmaceuticals·Stock Market

Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29

Viking heads into earnings week as its shares face downward pressure. The stock dropped 6.2% last week, with a 1.7% decrease on Friday.

26 July 2026

Biotechnology·Earnings Reports·NASDAQ:VKTX·Pharmaceuticals·Stock Market

SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation

NEW YORK, July 26, 2026, 14:22 EDT — With U.S. markets now closed, SELLAS Life Sciences stock ended down 14% as investors grew cautious waiting for updates on the REGAL program, testing the company's $2.2 billion market value.

26 July 2026

Biotechnology·NASDAQ:SLS·Pharmaceuticals·Stock Market

Iovance Shares Close Unchanged After Choppy Trading; 2026 Sales Target Puts Pressure on Growth Pace

Iovance Biotherapeutics closed at $4.99 on Friday, marking a 2.7% decline and finishing 0.2% lower than the previous Friday's close. The stock had reached a 52-week peak of $5.64 during Wednesday's session.

25 July 2026

Biotechnology·NASDAQ:IOVA·Stock Market

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Outlook Therapeutics, Inc. received U.S. clearance for Lytenava on Friday. Trading in its shares was paused following the news.

24 July 2026

Biotechnology·NASDAQ:OTLK·Pharmaceuticals·Stock Market

Biotechnology 24 July 2026 - 7 August 2026

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point

BillionToOne (NASDAQ:BLLN) shares drop 39% after maintained guidance signals weaker second half

Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions

Autonomix Medical (NASDAQ:AMIX) Shares Surge 400% Following Patent Update Linked to a 2025 Grant

Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold

Vertex Pharmaceuticals lifts forecast as non-CF portfolio heads into 53% second-half hurdle

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Replimune (NASDAQ:REPL) Shares Surge, Gaining Nearly $600 Million in Equity Value Following FDA Decision

GlucoTrack, Inc. (NASDAQ:GCTK) surges 95% after LT-100 news, market eyes dilution impact

Autonomix Medical, Inc. (NASDAQ:AMIX) rises as cash-per-share differential aligns with warrant overhang

Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap

Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data

CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test

Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29

SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation

Iovance Shares Close Unchanged After Choppy Trading; 2026 Sales Target Puts Pressure on Growth Pace

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

TechStock² Updates

Atlassian shares surge 32% on strong cloud forecast, offsetting Data Center slowdown

Applied Optoelectronics (NASDAQ:AAOI) surges 14% premarket as production boosts lead margin gains

Cloudflare (NYSE:NET) jumps 16% as AI-led beat lifts second-half sales plan

Ford (NYSE:F) shares extend six-session drop, $28,350 Fathom EV margins scrutinized

Figma (NYSE:FIG) share price under pressure as 77.7 million shares come off lock-up following earnings slump

Top Stock Picks

Constellation Energy

AerCap

Walt Disney

AIG

Cheniere Energy

Live updates

Investment Disclaimer